195 related articles for article (PubMed ID: 9334743)
1. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2.
Lawrie AM; Noble ME; Tunnah P; Brown NR; Johnson LN; Endicott JA
Nat Struct Biol; 1997 Oct; 4(10):796-801. PubMed ID: 9334743
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
De Azevedo WF; Mueller-Dieckmann HJ; Schulze-Gahmen U; Worland PJ; Sausville E; Kim SH
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2735-40. PubMed ID: 8610110
[TBL] [Abstract][Full Text] [Related]
3. Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors.
Toledo LM; Lydon NB
Structure; 1997 Dec; 5(12):1551-6. PubMed ID: 9438871
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for chemical inhibition of CDK2.
Kim SH; Schulze-Gahmen U; Brandsen J; de Azevedo Júnior WF
Prog Cell Cycle Res; 1996; 2():137-45. PubMed ID: 9552391
[TBL] [Abstract][Full Text] [Related]
5. Chemical inhibitors of cyclin-dependent kinases.
Meijer L; Kim SH
Methods Enzymol; 1997; 283():113-28. PubMed ID: 9251015
[No Abstract] [Full Text] [Related]
6. Stoichiometry of cyclin A-cyclin-dependent kinase 2 inhibition by p21Cip1/Waf1.
Adkins JN; Lumb KJ
Biochemistry; 2000 Nov; 39(45):13925-30. PubMed ID: 11076534
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.
Russo AA; Jeffrey PD; Patten AK; Massagué J; Pavletich NP
Nature; 1996 Jul; 382(6589):325-31. PubMed ID: 8684460
[TBL] [Abstract][Full Text] [Related]
8. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.
Hoessel R; Leclerc S; Endicott JA; Nobel ME; Lawrie A; Tunnah P; Leost M; Damiens E; Marie D; Marko D; Niederberger E; Tang W; Eisenbrand G; Meijer L
Nat Cell Biol; 1999 May; 1(1):60-7. PubMed ID: 10559866
[TBL] [Abstract][Full Text] [Related]
9. X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research.
Furet P
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):15-23. PubMed ID: 12678911
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of a viral cyclin, a positive regulator of cyclin-dependent kinase 6.
Schulze-Gahmen U; Jung JU; Kim SH
Structure; 1999 Mar; 7(3):245-54. PubMed ID: 10368294
[TBL] [Abstract][Full Text] [Related]
11. Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression.
Hashimoto Y; Kohri K; Kaneko Y; Morisaki H; Kato T; Ikeda K; Nakanishi M
J Biol Chem; 1998 Jun; 273(26):16544-50. PubMed ID: 9632724
[TBL] [Abstract][Full Text] [Related]
12. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
Schulze-Gahmen U; Brandsen J; Jones HD; Morgan DO; Meijer L; Vesely J; Kim SH
Proteins; 1995 Aug; 22(4):378-91. PubMed ID: 7479711
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition.
Komander D; Kular GS; Bain J; Elliott M; Alessi DR; Van Aalten DM
Biochem J; 2003 Oct; 375(Pt 2):255-62. PubMed ID: 12892559
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of potent CDK1 inhibitors derived from olomoucine.
Furet P; Zimmermann J; Capraro HG; Meyer T; Imbach P
J Comput Aided Mol Des; 2000 Jul; 14(5):403-9. PubMed ID: 10896313
[TBL] [Abstract][Full Text] [Related]
16. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity.
Kriwacki RW; Hengst L; Tennant L; Reed SI; Wright PE
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11504-9. PubMed ID: 8876165
[TBL] [Abstract][Full Text] [Related]
17. Under arrest at atomic resolution.
Morgan DO
Nature; 1996 Jul; 382(6589):295-6. PubMed ID: 8684452
[No Abstract] [Full Text] [Related]
18. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate.
Davies TG; Tunnah P; Meijer L; Marko D; Eisenbrand G; Endicott JA; Noble ME
Structure; 2001 May; 9(5):389-97. PubMed ID: 11377199
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.
Jeffrey PD; Russo AA; Polyak K; Gibbs E; Hurwitz J; Massagué J; Pavletich NP
Nature; 1995 Jul; 376(6538):313-20. PubMed ID: 7630397
[TBL] [Abstract][Full Text] [Related]
20. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
Brown NR; Noble ME; Endicott JA; Johnson LN
Nat Cell Biol; 1999 Nov; 1(7):438-43. PubMed ID: 10559988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
